Sun Pharmaceutical Industries Limited has made a significant announcement regarding its groundbreaking product, CEQUA (cyclosporine ophthalmic solution) 0.09%. The company has unveiled Phase 4 data showcasing CEQUA’s exceptional ability to induce sustained improvement in the signs and symptoms of dry eye disease (DED). CEQUA is an immunosuppressant and calcineurin inhibitor designed to enhance tear production […]
Sun Pharmaceutical Industries Ltd. has received approval from the U.S. Food and Drug Administration (FDA) for CEQUA (cyclosporine ophthalmic solution) 0.09%, a significant advancement in the treatment of keratoconjunctivitis sicca, commonly known as dry eye disease. This approval introduces a new therapeutic option for a condition that affects millions worldwide, addressing a substantial unmet medical […]
